Write a note on drug likeness screening for 1o marks
Reading File
Finding Sources
Finding Sources
Searching the Web
drug likeness screening Lipinski rule of five ADME pharmacology
Reading File
Finding Sources
Finding Sources
I now have enough information to write a thorough, exam-quality note. Here is the full answer:
Drug-Likeness Screening
Definition
Drug-likeness screening is a process used in early drug discovery to predict whether a candidate compound will possess the physicochemical and pharmacokinetic properties required for it to behave as an effective oral drug in humans. It does not assess pharmacological activity directly but instead evaluates whether a molecule is likely to be adequately absorbed, distributed, metabolized, and excreted (ADME) once administered. The goal is to filter out unsuitable compounds early and reduce costly late-stage failures in preclinical and clinical development.
Why Drug-Likeness Matters
A compound may bind its target with high affinity in vitro yet fail as a drug because it:
- Cannot be absorbed through the gastrointestinal tract
- Is too rapidly metabolized before reaching the site of action
- Is too toxic or reactive with off-target biomolecules
- Cannot be formulated into a stable, water-soluble dosage form
Drug-likeness screening applies empirical rules and computational filters to identify these problems at the hit-to-lead optimization stage, saving enormous time and resources.
Lipinski's Rule of Five (Ro5)
The most widely used drug-likeness guideline is Lipinski's Rule of Five, formulated by Christopher Lipinski at Pfizer in 1997, based on analysis of orally administered drugs in the World Drug Index.
The rule states that poor oral absorption or permeation is likely if a compound violates more than one of the following criteria:
| Parameter | Threshold |
|---|---|
| Molecular weight (MW) | ≤ 500 Daltons |
| Lipophilicity (LogP) | ≤ 5 (octanol-water partition coefficient) |
| Hydrogen bond donors (HBDs) | ≤ 5 (sum of -OH and -NH groups) |
| Hydrogen bond acceptors (HBAs) | ≤ 10 (sum of N and O atoms) |
| Molar refractivity | 40 - 130 (sometimes included) |
All thresholds are multiples of five - hence the name "Rule of Five."
Rationale:
- High molecular weight reduces passive membrane permeability
- High LogP indicates excessive lipophilicity, reducing aqueous solubility and risking off-target toxicity
- Too many HBDs impair membrane permeation (polar surface area increases)
- Too many HBAs reduce oral bioavailability
The Ro5 is the cornerstone of drug-likeness evaluation, though it applies best to orally bioavailable, small-molecule drugs and does not apply to biologics, natural products, or drugs delivered by non-oral routes (inhalation, transdermal, ophthalmic).
Other Drug-Likeness Filters
Several complementary filters extend or refine the Ro5:
1. Veber's Rules (GSK, 2002)
Focuses on oral bioavailability in rats. A compound should have:
- Rotatable bonds ≤ 10 (molecular flexibility)
- Polar surface area (PSA) ≤ 140 Ų or ≤ 12 H-bond donors + acceptors
These parameters predict intestinal absorption independent of molecular weight.
2. Ghose Filter (Amgen)
- MW between 160 - 480 Da
- LogP between -0.4 and +5.6
- Molar refractivity between 40 and 130
- Total atom count between 20 and 70
3. Egan Filter (Pharmacia)
Predicts passive intestinal absorption:
- PSA ≤ 131.6 Ų
- ALOGP ≤ 5.88
4. Muegge Filter (Bayer)
Broader criteria covering more drug classes:
- MW: 200-600 Da
- LogP: -2 to +5
- PSA ≤ 150 Ų
- Number of rings ≤ 7
5. Lead-Like Rule (Rule of Three, Ro3)
Proposed for screening library fragments used in fragment-based drug discovery (FBDD):
- MW ≤ 300 Da
- LogP ≤ 3
- HBDs ≤ 3
- HBAs ≤ 3
- Rotatable bonds ≤ 3
- PSA ≤ 60 Ų
This allows medicinal chemists to "grow" fragments into optimized leads while staying within Ro5 boundaries.
ADME Parameters in Drug-Likeness
Drug-likeness screening is directly tied to predicting ADME:
- Absorption - Governed by solubility, permeability, and stability in the GI tract. LogP, PSA, and HBD/HBA count determine passive permeation across intestinal epithelium.
- Distribution - LogP and plasma protein binding determine tissue penetration and volume of distribution. CNS drugs typically require LogP 1-3 and low PSA (<90 Ų).
- Metabolism - Metabolic stability is estimated by detecting reactive functional groups (e.g., Michael acceptors, epoxides) - so-called PAINS (Pan-Assay Interference Compounds) and metabolic soft spots.
- Excretion - Renal clearance depends on molecular size, polarity, and plasma protein binding.
Computational Tools for Drug-Likeness Screening
Modern drug discovery employs several in silico platforms:
| Tool | Use |
|---|---|
| SwissADME | Free web tool; calculates Ro5, Veber, Ghose, Egan, Muegge filters simultaneously |
| ADMET Predictor | Predicts absorption, toxicity, metabolism endpoints |
| FAF-Drugs | Filters compound libraries by multiple drug-likeness rules |
| PAINS Filters | Identifies pan-assay interference compounds - false-positive hits in HTS |
| QED (Quantitative Estimate of Drug-likeness) | Single score (0-1) integrating MW, LogP, HBD, HBA, PSA, rotatable bonds, aromaticity, and alerts |
High-Throughput Screening (HTS) and Drug-Likeness
In High-Throughput Screening, large compound libraries (hundreds of thousands to millions of molecules) are tested against a target. Drug-likeness filters are applied before and after HTS to:
- Pre-filter compound libraries (remove non-drug-like molecules before screening)
- Triage hits (remove PAINS and compounds with reactive/toxic substructures)
- Prioritize lead compounds for medicinal chemistry optimization
This significantly reduces the number of compounds requiring expensive biological testing.
Limitations of Drug-Likeness Rules
- The Ro5 was derived from oral drugs and does not apply to:
- Biologics (antibodies, peptides)
- Drugs given by non-oral routes
- Natural products (e.g., cyclosporine violates Ro5 yet is bioavailable)
- Rules are probabilistic, not absolute - many marketed drugs violate one or more criteria
- Drug-likeness does not predict pharmacodynamic activity - a compound can be drug-like but inactive
- Newer modalities (PROTACs, macrocycles, covalent drugs) require "beyond Ro5" (bRo5) frameworks with MW up to 1000 Da
Summary
Drug-likeness screening is a foundational strategy in modern drug discovery that uses empirical rules (primarily Lipinski's Ro5) and computational filters to predict whether a compound will have adequate ADME properties as an oral drug. By eliminating unsuitable candidates early, it substantially reduces attrition in clinical development and focuses medicinal chemistry resources on molecules with the highest probability of becoming safe, effective drugs. As drug modalities evolve beyond classical small molecules, drug-likeness frameworks continue to adapt to accommodate macrocycles, PROTACs, and covalent inhibitors.
Key References:
- Lipinski et al., Adv. Drug Deliv. Rev., 1997 - Original Rule of Five
- Goodman & Gilman's The Pharmacological Basis of Therapeutics, Medicinal Chemistry section (Rule of Five and drug discovery context)
- SwissADME - integrated drug-likeness prediction tool
This is a shared conversation. Sign in to Orris to start your own chat.